Table 2.
NRI between GRIT scores and clinical risk scores in UK Biobank.
| Upclassified to higher risk (%) | Both high risk (%) | Downclassified to lower risk (%) | Both low risk (%) | Category-based NRI [95% CI] | ||
|---|---|---|---|---|---|---|
| GRIT-CHD vs PCE | Cases | 428 (9.6%) | 320 (7.2%) | 221 (4.9%) | 3500 (78.3%) | 4.7 [3.6, 6.0] |
| Non-cases | 5463 (2.3%) | 3110 (1.3%) | 3864 (1.6%) | 225,781 (94.8%) | −0.7 [−0.8, −0.6] | |
| All | 5891 (2.4%) | 3430 (1.4%) | 4085 (1.7%) | 229,281 (94.5%) | 4.0 [3.0, 5.3] | |
| GRIT-CHD+ vs PCE | Cases | 616 (13.8%) | 411 (9.2%) | 130 (2.9%) | 3312 (74.1%) | 10.9 [9.7, 12.0] |
| Non-cases | 6903 (2.9%) | 4356 (1.8%) | 2618 (1.1%) | 224,341 (94.2%) | −1.8 [−1.9, −1.7] | |
| All | 7519 (3.1%) | 4767 (2.0%) | 2748 (1.1%) | 227,653 (93.8%) | 9.1 [7.9, 10.2] | |
| GRIT-T2D vs QDiabetes | Cases | 330 (13.0%) | 628 (24.7%) | 108 (4.2%) | 1478 (58.1%) | 8.7 [7.1, 10.4] |
| Non-cases | 4453 (3.8%) | 4603 (3.9%) | 1452 (1.2%) | 108,061 (91.1%) | −2.5 [−2.6, −2.4] | |
| All | 4783 (3.9%) | 5231 (4.3%) | 1560 (1.3%) | 109,539 (90.4%) | 6.2 [4.6, 7.8] | |
| GRIT-T2D+ vs QDiabetes | Cases | 463 (18.2%) | 654 (25.7%) | 82 (3.2%) | 1345 (52.9%) | 15.0 [13.1, 16.7] |
| Non-cases | 5840 (4.9%) | 4727 (4.0%) | 1328 (1.1%) | 106,674 (90.0%) | −3.8 [−3.9, −3.7] | |
| All | 6303 (5.2%) | 5381 (4.4%) | 1410 (1.2%) | 108,019 (89.2%) | 11.1 [9.3, 12.9] |
The reclassification numbers and proportion of cases, non-cases, and all participants were assessed alongside the category-based net reclassification improvement (event NRI, nonevent NRI, overall NRI) by comparing the Genomics-enhanced RIsk Tools (GRIT-CHD and GRIT-CHD+ for CHD, GRIT-T2D and GRIT-T2D+ for T2D) to established clinical risk scores (PCE for CHD and QDiabetes for T2D). Based on the established clinical risk scores, the thresholds for 10-year risk were 7.5% for CHD and 5.6% for T2D.